Please be aware that all information shared here at Canada Pharmacy has been medically reviewed and fact-checked for accuracy. These verifications are made by board-certified medical professionals who have the authority required to state that information related to medical conditions, symptoms, procedures and tests, and standard treatment protocols is valid and truthful. This is based on current guidelines and consensuses shared amongst medical professionals, and in representation of the latest research.
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
SOLIQUA 100/33 (insulin glargine and lixisenatide) is a prescription drug for people with type 2 diabetes mellitus. It is used to treat high blood sugar (hyperglycemia) and to improve glycemic control.
SOLIQUA insulin glargine/lixisenatide should be used in combination with diet and exercise.
Inject SOLIQUA 100/33 subcutaneously once daily. Inject within one hour before the first meal of the day.
The two possible starting doses are:
The prescriber will determine the starting dose, and it is based on how much insulin you normally use. Over time, the dose can be increased to a maximum of 60 units/20 micrograms.
SOLIQUA contains two ingredients: a long-acting insulin and a GLP-1 receptor agonist.
Insulin glargine is a long-acting insulin that is administered once daily to achieve glycemic control for about 24 hours.
Lixisenatide is a GLP-1 receptor agonist. It works by slowing down food that moves through the gastrointestinal tract and causing the pancreas to release extra insulin.
The following medications can raise or lower blood sugar. Use caution and tell your doctor if you are taking:
Certain drugs can mask the symptoms of low blood sugar. Use caution if you are taking:
Lixisenatide slows down the gastrointestinal tract and may affect the absorption of some drugs. Take these drugs one hour before or 11 hours after SOLIQUA 100/33:
Your doctor should monitor kidney function, liver function, and potassium levels. Tell your doctor if you have a history of cardiovascular disease.
Tell your doctor if you have a history of pancreatitis.
Read the SOLIQUA 100/33 label carefully before each injection to prevent medication errors.
Some of the most common side effects of SOLIQUA 100/33 may include: